Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-masked, vehicle-controlled study of the safety and efficacy of
OTX-101 (0.09% cyclosporine nanomicellar solution) in the treatment of keratoconjunctivitis
sicca to be conducted at approximately 50 sites.